Christopher O Reilly: Thank you for taking time out of your very busy schedule to join us for the FY 22 Q3 Earnings Announcement by Takeda. My name is O Reilly, Head of IR.
Asia Deal Watch: Kelun Partners With Merck A Third Time, Optioning Rights To Seven ADCs informa.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from informa.com Daily Mail and Mail on Sunday newspapers.
Japan: Takeda has announced that it will acquire NDI-034858 from Nimbus Therapeutics. NDI-034858 is an oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor being evaluated for the treatment.